Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma

Mehrzad, Valiollah; Ashrafi, Farzaneh; Farrashi, Ali Reza; Pourmarjani, Reyhaneh; Dehghani, Mehdi; Shahsanaei, Armindokht

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma

Document Type : Original Article

Authors

¹ Department of Hematology and Medical Oncology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

² Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

³ Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Departments of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran

⁵ Medical School, Research Deputy of Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Refractory or relapsed Hodgkin's disease (HD) occurs in 10-50% of patients. The treatment of choice for these patients is high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). Response to salvage chemotherapy (SCT) partial remission (PR) is necessary before HDCT with ASCT. However, its applicability is restricted mostly to patients responding to salvage chemotherapy. Optimal salvage regimen for these patients is unclear. In this study, our aim was to compare the efficacy profiles of ifosfamide, carboplatin, and etoposide (ICE) and etoposide-steroid-cytarabine-cisplatin (ESHAP) (cytosine arabinoside, cisplatin, and dexamethasone) regimens in the salvage treatment of relapsed or refractory HD. Materials and Methods: In this retrospective analysis, 114 patients with primary refractory or relapsed HD who received ICE or ESHAP salvage regimen were included. Results: Of 114 patients, 47 (41.2%) were females and the median age was 31.5 years. Response could be evaluated in 114 patients. Of 114 patients, 38 (33%) achieved complete remission (CR) and 21 (18.4%) achieved PR, leading to an overall response rate (ORR: CR + PR) of 51.4%. In the evaluable ICE group (n = 41), rates of CR, PR, and ORR were 21.9%, 17.1%, and 39% and in the ESHAP group (n = 73), rates of CR, PR, and ORR were 39.7%, 19.2%, and 58.9% (for ORR,P = 0.04), respectively. Conclusion: In patients with relapsed or refractory HD, treatment with ESHAP seems to have higher rates of response than ICE regimen does.

Keywords

References

1.	Longo D. Malignancies of lymphoid cells. In: Fauci A, Kasper D, Longo D, Braunwald E, Hauser S, Jameson J, et al.,editors. Harrison's internal medicine. 17^th ed. New York: Mc Graw-Hill Companies; 2008. p. 698-9.
2.	Lacy J, Seropian S. Disorders of lymphocytes. In: Carpenter CH, Griggs R, Loscalzo J, editors. Cecil essentials of medicine. 6^th ed. Philadelphia: WB Saunders Company; 2004. p. 472-4.
3.	DeVita VT Jr. A selective history of the therapy of Hodgkin's disease. Br J Haematol 2003;122:718-27.
4.	Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, et al . Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26:401-6.
5.	Aleman BM, Raemaekers JM, Tirelli U, Bortolus R, van't Veer MB, Lybeert ML, et al . Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003;348:2396-406.
6.	Cheson BD. What is new in lymphoma? CA Cancer J Clin 2004;54:260-72.
7.	Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
8.	Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al . Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
9.	Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
10.	Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, et al . Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6.
11.	Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al . ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-205.
12.	Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al . Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987;5:27-37.
13.	Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, et al . High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 2005;16:1359-65.
14.	Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993;341:1051-4.
15.	Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004;124:645-52.
16.	Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
17.	Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al . Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002;359:2065-71.
18.	Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, et al . Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-13.
19.	Hamlin PA, Zelenetz AD, Kewalramani T, Qin J, Satagopan JM, Verbel D, et al . Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003;102:1989-96.
20.	Moskowitz CH, Nimer SD, Glassman JR, Portlock CS, Yahalom J, Straus DJ, et al . The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma. Bone Marrow Transplant 1999;23:561-7.
21.	Olivieri A, Brunori M, Capelli D, Montanari M, Massidda D, Gini G, et al . Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: An intention to mobilize and transplant analysis. Eur J Haematol 2004;72:10-7.
22.	Abali H, Oyan B, Koc Y, Kars A, Barista I, Uner A, et al . IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am J Clin Oncol 2005;28:264-9.
23.	Jerkeman M, Leppä S, Kvaløy S, Holte H. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma: The Nordic Lymphoma Group experience. Eur J Haematol 2004;73:179-82.
24.	Josting A, Rudolph C, Mapara M, Glossmann JP, Sieniawski M, Sieber M, et al . Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005;16:116-23.
25.	Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al . Time-intensified dexamethasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002;13:1628-35.
26.	Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, et al . Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-85.
27.	Salar A, Martino R, Perea G, Ribera JM, López-Guillermo A, Guardia R, et al . High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma. Haematologica 2002;87:1028-35.
28.	Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, et al . ESHAP: An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994;12:1169-76.
29.	Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al . Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-22.
30.	Wang WS, Chiou TJ, Liu JH, Fan FS, Yen CC, Tung SL, et al . ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience. Jpn J Clin Oncol 1999;29:33-7.
31.	Imataki O, Tamai Y, Kawakami K. Comparison of salvage chemotherapy regimen ACES with ESHAP for refractory or relapsed malignant lymphoma. Gan To Kagaku Ryoho 2007;34:1629-32.
32.	Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2006;47:1306-14.
33.	Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
34.	Moskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002;49:S9-12.
35.	Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990;5:99-103.
36.	Aparicio J, Segura A, Garcerá S, Oltra A, Santaballa A, Yuste A, et al . ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 1999;10:593-595.
37.	Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
38.	Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al . The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group. Blood 1998;92:3562-8.
39.	Horning S. Hodgkin lymphoma. In: Lichtman M, kipps T, Kaushansky K, Beutler E, Seligsohn U, Prchal J, editors. Williams Hematology. 7^th ed. New York: Mc Graw-Hill Companies; 2006. p. 1468-74.
40.	Stein R, Morgan D. Hodgkin lymphoma. In: Greer J, Foester J, Rodgers G, Paraskevas F, Glader B, Arber D, et al . Wintrobe's Clinical Hmatology. 12^th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 2330-1.
41.	Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506-14.

Advanced Biomedical Research